Unexpected Ownership in Life Sciences: A Lender’s Guide to the First 100 Days

Kaile Zagger
November 16, 2026

Share:

Riveron Viewpoints: In this opinion section, Riveron professionals share their personal take on current topics relevant for today’s CFOs and other business leaders.

Lender-owners inherit clinical trials, regulatory responsibilities, and a business that depends on specialized expertise. Here’s how to set priorities and bring in the people needed to keep a Life Sciences organization running. 

 

In the life sciences sector, private credit has quietly become one of the most important sources of capital. No lender makes a loan expecting to own a life sciences company, especially when it’s in the middle of a heavily regulated clinical trial. But in life sciences, where value can hinge on one trial readout or FDA decision, a restructuring can hand a credit team a drug program overnight, leaving them holding equity in a business they never intended to own. They become, in effect, accidental owners, and few lending teams are built for that role. Yet once lenders hold the keys, the employees, partners, regulators and, above all, patients depend on how well they carry it. 

For lenders in that position, or those who may be one day, a proactive approach can keep essential assets running through a change of hands. Private credit lenders to life sciences companies and other FDA-regulated companies should plan for the possibility of unexpected ownership now. To be effective in these situations, lenders should understand what they would own, structure loans to make ownership less likely, and take steps in advance to line up operators and a hold-or-sell plan. 

 

A LOOK AHEAD: 

Why unexpected ownership happens 

The odds, the market, and policy shocks 

Nuances of ownership in the life sciences sector 

Six things lender-owners need to know on Day 1 

How lenders can prevent having to step in 

Four lender strategies that reduce the odds of ownership 

What lenders can do if they become owners 

Who should run the life sciences business, and a 100-day plan 

 

Why lenders in the life sciences sector end up as owners 

In the life sciences industry, the odds explain a lot. Across more than 12,000 clinical transitions studied by the Biotechnology Innovation Organization, programs entering Phase III reached approval about 52% of the time, and oncology programs less than half the time. On a four-year, $150 million loan at an 11% interest rate, the lender earns about $66 million, but a failed program (about 48% of the time) with a 30-cent recovery implies an expected loss of roughly $50 million. The loan behaves like a high-risk option, and the premium is thin. 

Debt increasingly finances the middle: biotech companies too advanced for another venture round, as equity concentrates in fewer, larger winners and isn’t yet attractive to buyers. That’s where distress builds. Public life sciences companies recorded 46 bankruptcies in 2024 and 2025, and 19 had meaningful revenue. Approval isn’t solvency. Policy shocks add pressure: 

  • BIOSECURE. The BIOSECURE Act, enacted last December, will restrict reliance on designated “biotechnology companies of concern,” a category aimed largely at Chinese suppliers, from roughly 2028. 

 

What lenders need to know on Day 1 

A lender-owner needs a clear picture of six things. If management has them ready, that signals a well-run company, and it makes due diligence easier. If not, lenders need to work with management to build the file together first. 

Key factors in the Life Sciences sector 

Where lender-owners need clarity and focus 

1  

Permissions 

Moving an approved drug application requires letters from both the former and new owner. DEA registrations can’t transfer without written consent. State licenses are often reissued. 

2 

Intellectual property 

Patent title, recorded security interests, and in-licenses that end or reprice on a change of control. Six of the 19 first financings of $50 million or more in the first half involved assets licensed from China. 

3 

Counterparties 

The contract manufacturer, in-licensors, and the contract research organization running any pivotal trial. Agree in advance on notice, cure time, and willingness to work with a new owner. 

4 

Supply and quality 

Each contract manufacturer and the time to qualify an alternative. Requalification typically takes 18 to 24 months or longer, so the BIOSECURE timetable matters now. 

5 

People 

The few manufacturing, quality, regulatory, and clinical professionals who hold the knowledge behind the approval. They are the business. Retain them and be candid about what’s happening. 

6 

Obligations that can’t lapse 

Drug-safety reporting, ongoing trials, and commitments to patients. A lapse can impair the approval, and a halted clinical trial harms patients and destroys data, so these matters must be treated as top priority. 

 

Lender strategies: structure loans so ownership is less likely 

Much unwanted ownership traces back to loan structures and risk management practices that ignore the company’s timeline. Here, four changes help: 

  • Catalyst coverage ratio. Replace a static minimum-liquidity test with unrestricted cash divided by projected burn through the next binary event (a trial readout or FDA decision) plus 12 months, held at or above 1.0 times. If the FDA extends a review, as it may by three months after a major amendment, the test should reset. 
  • Maturity set against exclusivity. Maturity should fall at least three years before patent and regulatory protection ends, so the company isn’t forced into a refinancing it can’t win. 

 

Lenders who take ownership of a life sciences company in distress must bring in the right operators 

In the life sciences sector, the most consequential decision is who runs the business. Keeping scientists and partners confident, sustaining an inspection-ready quality system, and working with regulators are skills built over careers in approval and launch. Even the most savvy credit teams won’t have this expertise. Successful guidance starts with the existing management team, and lender-owners can support them with clear priorities, funding, and honest communication. Where gaps exist, interim leaders in quality, regulatory affairs, and finance can add credibility that no creditor can. Line up names and retention plans in advance so that capable help can be mobilized at the first sign of potential distress. 

 

Rehearse the first 100 days 

For each significant credit, run a tabletop exercise with counsel, prospective operators, the company’s regulatory staff, and, where relevant, the private equity sponsor. It should answer three questions: 

  • Which filings would we need to make on Day 1, and which approvals couldn’t we secure within 90 days? 
  • Which partners might step back, and which have confirmed they’ll continue? 
  • Should we steward this business for a period, or move it promptly to a new long-term owner? 


Tie the last answer to the catalyst calendar. Commercial-stage companies, contract manufacturers, and makers of medical devices with cleared products keep their value in assets that survive a change of ownership, so the right operators can steward them well. Clinical-stage assets are options, and options decay. With buyers paying
median upfront purchase prices near $1 billion for venture-backed companies, a timely sale often beats a long hold. 

It’s also critical to check the lender’s own regulatory perimeter because the antitrust premerger exemption for creditors is narrower than many assume, and foreign limited partners taking over a company with sensitive genetic data may trigger a Committee on Foreign Investment in the United States review. And for any product that depends on one overseas manufacturer, well-informed teams will qualify a second source. 

A question for limited partners: LPs should ask their managers, “If you owned one of your largest life sciences borrowers tomorrow, who would run it, which patient and regulatory obligations would you honor in the first week, and would you hold or sell?” Thoughtful answers show a manager has considered the responsibility, not just the return. 

 

Plan for the unexpected before restructuring and turnaround work begins 

Lenders can’t rule out owning a borrower, but they can decide in advance how they’d handle it: know what they’d hold, structure loans around the company’s timeline, and have capable operators ready to step in. Lenders that do this well protect patients and value alike, and the best time to plan for these possibilities is before the need for a turnaround becomes a reality. 

Manufacturing a missile may take weeks. Building the supply chain that makes that missile possible can take years. The demand is at the front. The money isn't getting there.

~€7B

Airbus inventory increase through Q3 2024, with the company citing inventory build-up supporting fourth-quarter deliveries and the ramp-up across programs

Airbus – 9M 2024 Results

$63M

Hexcel working-capital cash use in Q1 2026, even as sales increased approximately 10% YoY

Hexcel – Q1 2026 Results

+181M/+70M/+101M 

Woodward increase from Sept. 2025 to June 2026 in accounts receivable / inventory / PP&E, illustrating capital tied up as the business grows


Woodward – Q3 FY2026 Results / SEC Filing

The defense industrial base – a structural warning 

The Pentagon’s consolidation decisions of the 1990s—from 51 prime contractors to 5, with commensurate compression of the subprime tier—built a defense industrial base optimized for peacetime procurement efficiency and zero surge capacity. What felt like smart portfolio management in 1993 is a national security liability in 2026. Rebuilding that industrial base is a decade-long project. The multi-year contract authorities and production agreements being signed today are necessary but insufficient without simultaneous capital relief for the supplier base that has to execute them. 

The bottom line

The demand signal for US aerospace and defense manufacturing is historically strong across every segment simultaneously. The industrial base is not structurally equipped to satisfy it — not in terms of physical capacity, not in terms of qualified workforce, and not in terms of the financial health of the middle market manufacturers who form its backbone. The investment cycle has started, but it is running 18 to 36 months behind the demand curve, and the liquidity constraints at Tier 2 and below are acting as an invisible governor on execution.

Connect with an expert

Kaile Zagger

Kaile Zagger

Healthcare & Life Sciences Leader

READ BIO

Want to Learn More?

In life sciences, healthcare, and other highly-regulated sectors, Riveron professionals provide lender advisory and other support to creditors, investors, and companies navigating distress or seeking to elevate performance. We help stabilize operations and guide stakeholders through complex situations. To talk through your own portfolio, contact our team. 

More Insights

Contact us​

Continue the conversation. Reach out to Riveron’s team of professionals to explore how we can provide the clarity and insight to solve your organization’s most pressing challenges.

Sign up for our newsletter

Stay informed with Riveron Insights delivered to your inbox.

Add Your Heading Text Here

Riveron’s operational expertise helps you design and implement practical solutions that improve processes, strengthen controls, and position accounting and finance functions for growth.

Program change management

With industry focus, speed, and agility, our interim executives help both private equity and corporate clients maintain their momentum to drive transformational change. Our professionals deliver lasting, bespoke results to achieve our clients’ goals.